Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Mon, 05.09.2022
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the approval of the Supervisory Board on the same day, to increase the Company's share capital from Authorized Capital 2022/I. aap's share capital shall be increased from its current level of EUR 5,960,737.00 by EUR 596,073.00 to EUR 6,556,810.00 by issuing 596, [ … ]
Mon, 05.09.2022
aap Implantate AG
The Management Board of aap Implantate AG ("aap" or the "Company") today resolved, with the approval of the Supervisory Board on the same day, to increase the Company's share capital from Authorized Capital 2022/I. aap's share capital shall be increased from its current level of EUR 5,960,737.00 by EUR 596,073.00 to EUR 6,556,810.00 by issuing 596, [ … ]
Fri, 12.08.2022
aap Implantate AG
Sales: Q2 at EUR 2.7 million (‑17 % yoy) and H1 at EUR 5.6 million (‑7 % yoy); growth trend intact with LTM sales up 7 %[1]
EBITDA: Q2 at EUR ‑0.2 million (Q2/2021: EUR +0.3 million) and H1 at EUR ‑0.7 million (H1/2021: EUR +0.1 million) impacted by sales decline, planned build-up of sales infrastructure, conduction of human clinical trial and wor [ … ]
Fri, 12.08.2022
aap Implantate AG
Sales: Q2 at EUR 2.7 million (‑17 % yoy) and H1 at EUR 5.6 million (‑7 % yoy); growth trend intact with LTM sales up 7 %[1]
EBITDA: Q2 at EUR ‑0.2 million (Q2/2021: EUR +0.3 million) and H1 at EUR ‑0.7 million (H1/2021: EUR +0.1 million) impacted by sales decline, planned build-up of sales infrastructure, conduction of human clinical trial and wor [ … ]
Thu, 28.07.2022
aap Implantate AG
Publication of inside information pursuant to Art. 17 MAR
The Management Board of aap Implantate AG ("aap" or the "Company") is issuing an update for the second quarter of 2022 and revising its guidance for the financial year 2022 after macroeconomic conditions have not improved in the second quarter of 2022 and the general market environment in [ … ]
Thu, 28.07.2022
aap Implantate AG
Publication of inside information pursuant to Art. 17 MAR
The Management Board of aap Implantate AG ("aap" or the "Company") is issuing an update for the second quarter of 2022 and revising its guidance for the financial year 2022 after macroeconomic conditions have not improved in the second quarter of 2022 and the general market environment in [ … ]
Fri, 13.05.2022
aap Implantate AG
Sales: EUR 2.9 million (+6 % yoy); EMEA (+19 % yoy) and North America (+5 % yoy) as main growth drivers
EBITDA: EUR -0.5 million (Q1/2021: EUR -0.2 million) impacted by planned build-up of sales infrastructure and conduction of human clinical study
Silver: First surgeries performed as part of human clinical study for innovative silver antibacteri [ … ]
Wed, 06.04.2022
aap Implantate AG
aap Implantate AG ("aap" or the "Company") announces that in the first quarter of 2022 the first surgeries were performed as part of the human clinical trial for its innovative antibacterial silver coating technology. The surgeries took place at the University Hospital Regensburg and went according to plan. aap had initiated the human clinical tria [ … ]
Thu, 31.03.2022
aap Implantate AG
- Sales: EUR 12.2 million (+30% yoy) - CER[1]: +32% yoy; all markets with significant double-digit growth rates
- EBITDA: EUR -0.8 million (+84% yoy); operating cash flow +33% yoy
- Silver: Start of human clinical study in December 2021 - already promising clinical data from individual healing trials beforehand
- Successful refinancing, in pa [ … ]
Mon, 24.01.2022
aap Implantate AG
- Sales +30% (FY/2021) to EUR 12.2 million and +34% (Q4) to EUR 3.2 million (CER[1]: +32% (FY/2021) and +38% (Q4))
- Significant double-digit growth rates in all regions in FY/2021: LATAM (+90%), EMEA (+26%), North America (+21%) and APAC (+20%)
- Extensive investments in sales structures and teams, particularly in North America and Germany, shal [ … ]